CHF Solutions, Inc. Begins New Educational Program, “Facing the Facts About Fluid Overload” to Demonstrate the Need for Aquadex Therapy

March 29, 2018

EDEN PRAIRIE, Minn., March 29, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today the launch of a new educational program, “Facing the Facts About Fluid Overload,” designed to inform providers about an alternative ultrafiltration therapy for heart failure patients with fluid overload who have failed diuretic therapy.

"Intravenous diuretics have been the standard of care for heart failure patients with fluid overload since the 1950s^1,2, but data demonstrates that 68 percent of patients experience a less than optimal response, and approximately 40 percent are resistant to diuretic therapy³. Many physicians simply are not aware that the Aquadex FlexFlow System can address the unmet clinical need for these patients when diuretic resistance is encountered,” commented Jim Breidenstein, chief commercial officer of CHF Solutions. “This educational program provides clinicians with compelling data about the limitations of IV diuretics, and the importance of having a proven and effective alternative therapy to assist in treating this large patient population.”

This educational campaign will also raise awareness of the potential economic impact that fluid overloaded patients may have on hospitals and the healthcare system. It has been shown in clinical trials that 24 percent of heart failure patients that are discharged from the hospital are readmitted within 30 days, and 50 percent within 6 months^4,5. Conversely, ultrafiltration therapy with the Aquadex FlexFlow system has demonstrated a 53 percent reduction in the risk of re-hospitalization of heart failure patients⁶. Further, data demonstrates that nearly half of all patients discharged from the hospital with heart failure are still fluid overloaded at time of discharge⁷. The Aquadex FlowFlow System provides a solution for safe and precise fluid removal for patients with volume overload who have failed diuretic therapy.

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

CONTACTS:

INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

Sources: 1. Freis ED, Wanko A, Wilson IM, et al. JAMA 1958;166 (2) 137- 140. 2. Moser M, Macauley AI, Am J Cardiol 1959;3 (2) 214- 219. 3. Testani JM, Hanberg JS, Cheng S, et al. Circ Heart Failure. 2016;9(1). 4. Ambrosy, Fonarow GC, Butler J, et al. J Am Coll Cardiol. 2014;63:1123-33. 5. Crespo-Leiro MG, Anker SD, Maggioni AP et al. Eur J Heart Fail 2016;18: 613-25. 6. Costanzo MR, Guglin ME, Saltzberg MT, et al. J Am Coll Cardiol. 2007;49(6):675-683. 7. Gheorghiade M and Flippatos G. Eur Heart J Suppl 2005;7: B13-19.